Evidence map›Paper›PMID 37274119›Full record

ArticleFrontiers in pharmacology2023

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC).

Antoine Le Bozec, Mathias Brugel, Zoubir Djerada, Marya Ayad, Marine Perrier, Claire Carlier, Damien Botsen, Pierre Nazeyrollas, Olivier Bouché, Florian Slimano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Antoine Le BozecCHU Reims, Oncology Day-Hospital, Reims, France.
Mathias BrugelCHU Reims, Service de Gastroentérologie et Oncologie Digestive, Reims, France.
Zoubir DjeradaUniversité de Reims Champagne-Ardenne, HERVI, Service Pharmacologie-Toxicologie, Reims, France.
Marya AyadCHU Reims, Oncology Day-Hospital, Reims, France.
Marine PerrierCHU Reims, Service de Gastroentérologie et Oncologie Digestive, Reims, France.
Claire CarlierCHU Reims, Oncology Day-Hospital, Reims, France.
Damien BotsenCHU Reims, Service de Gastroentérologie et Oncologie Digestive, Reims, France.
Pierre NazeyrollasUniversité de Reims Champagne-Ardenne, VieFra, CHU Reims, Service Cardiologie, Reims, France.
Olivier BouchéUniversité de Reims Champagne-Ardenne, Biospect, CHU Reims, Service de Gastroentérologie et Oncologie Digestive, Reims, France.
Florian SlimanoUniversité de Reims Champagne-Ardenne, Biospect, CHU Reims, Service Pharmacie, Reims, France.
Centre Hospitalier Universitaire de Reims · FRUniversité de Reims Champagne-Ardenne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adrenergic beta-antagonistscardiovascular diseasesdrug repositioningpancreatic neoplasmspharmacoepidemiogy

Identifiers

PMID37274119
PMCPMC10235451
OpenAlexW4377139631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.